Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
12,838 total articles
FTAI Aviation Ltd., a US-listed company (NASDAQ: FTAI), announced the successful pricing of its inaugural asset-backed securitization (ABS) under its Strategic Capital vehicle, raising $612 million through the issuance of two classes of investment grade notes backed by a portfolio of 48 narrowbody aircraft leased to 23 global airlines. The transact…
Yimutian Inc. announced the full deployment of its WolaiCai AI Agent across all platforms, achieving over 200 million daily token consumption and generating approximately US$3,000 in daily revenue from agricultural AI products. The AI agent improves transaction efficiency between buyers and sellers in agricultural trading by automating procurement …
Lixiang Education Holding Co., Ltd. announced successful compliance with Nasdaq's minimum bid price requirement following a 1-for-10 reverse stock split, resolving previous non-compliance issues and securing continued listing on the exchange.
NIO Inc., a leading global smart electric vehicle manufacturer, announced its Annual General Meeting to be held on June 24, 2026, in Shanghai. The company also released its annual report (Form 20-F) for the fiscal year ended December 31, 2025, filed with the U.S. SEC. NIO's board supports the proposed resolutions to be voted on at the AGM. Voting i…
BioNTech SE announced encouraging clinical trial updates from its late-stage oncology pipeline at the 2026 ASCO Annual Meeting. Data highlights include positive anti-tumor activity of pumitamig in first-line non-small cell lung cancer and gotistobart showing durable activity in platinum-resistant ovarian cancer. The company continues to advance ove…
NervGen Pharma Corp., a clinical-stage biopharmaceutical company focused on neuroreparative therapies, announced an underwritten public offering of 24 million common shares and accompanying warrants priced at $2.50 each, raising approximately $60 million before expenses. The proceeds will be used to advance their lead candidate NVG-291 through clin…
Yimutian Inc., a China-based agricultural digital services company listed on Nasdaq, has submitted a hearing request to the Nasdaq Hering Panel after receiving a defiency notification related to minimum market value listing standards. The submission halts any delisting process pending the hearing outcome. Yimutian is executing strategic initiatives…
Medline Inc. has priced an upsized secondary offering of approximately 72.55 million shares of its Class A common stock by selling stockholders affiliated with Blackstone, Hellman & Friedman, and Abu Dhabi Investment Authority at $37 per share. Medline itself is not selling shares nor receiving proceeds from the offering. The offering is expected t…
All In FutureTech Alliance Inc. (Nasdaq: AGAE) announced the filing of its 2025 Annual Report on Form 10-K, addressing previous Nasdaq compliance issues regarding late filings. With major litigation disputes resolved, the company aims to continue its strategic transformation from experiential entertainment to an AI-powered digital infrastructure pl…
Liminatus Pharma, a biopharmaceutical company focused on oncology and serious diseases therapies, received a Nasdaq delisting notification as it failed to meet the minimum market value of listed securities and publicly held shares criteria. The company intends to appeal the decision but faces suspension of its securities trading and removal from Na…
Rocket Lab Corporation has been awarded a $90 million contract by the U.S. Space Force's Space Systems Command to design, build, and operate two geostationary satellites equipped with Heimdall space domain awareness payloads. This marks Rocket Lab's entry into satellite production for geostationary orbit, extending its vertically integrated mission…
HUTCHMED announced that new and updated clinical data from several of its drug candidates, including savolitinib and fruquintinib, will be presented at the ASCO Annual Meeting 2026. Key highlights include positive Phase II results for savolitinib in MET-amplified gastric cancer with the primary endpoint met and priority review in China. Additional …
Ascentage Pharma announced clinical data from six abstracts presented at ASCO 2026 showcasing efficacy and safety results for its key drug candidates targeting various cancers including chronic myeloid leukemia and pediatric solid tumors. Ongoing Phase III trials for olverembatinib and lisaftoclax further support the company's growth potential in o…
Fennec Pharmaceuticals announced new independent research findings on PEDMARK®, its FDA-approved treatment to reduce cisplatin-induced ototoxicity, will be presented at the 2026 ASCO Annual Meeting. The studies demonstrate PEDMARK's safety, efficacy, and feasibility for use beyond pediatric populations, including adolescent, young adult, and adult …
Biogen and Denali Therapeutics announced that the Phase 2b LUMA study evaluating BIIB122 (DNL151), a LRRK2 inhibitor, in early-stage idiopathic Parkinson's disease failed to meet its primary and secondary endpoints, showing no slowing of disease progression. Consequently, they will discontinue BIIB122 development for idiopathic Parkinson's disease,…
Perspective Therapeutics, Inc. announced that it will present updated data from all three of its clinical programs—[212Pb]VMT-b1-NET for neuroendocrine tumors, [212Pb]VMT01 for melanoma, and [212Pb]PSV359 for solid tumors—at the 2026 ASCO Annual Meeting. The data show continued favorable safety profiles, evidence of tumor response, and no dose-lim…
Zentalis Pharmaceuticals announced encouraging Phase 1b clinical trial results from their MUIR study evaluating the investigational WEE1 inhibitor azenosertib combined with paclitaxel in platinum-resistant ovarian cancer patients. The combination showed a manageable safety profile and promising anti-tumor activity, notably a 39% overall response ra…
Crescent Biopharma announced the presentation of a trial in progress poster for their ASCEND Phase 1/2 global clinical trial of CR-001, a PD-1 x VEGF bispecific antibody targeting multiple solid tumors including NSCLC, gastrointestinal and gynecological cancers. Enrollment is ongoing worldwide, with initial clinical data expected starting Q1 2027. …
Peace Acquisition Corp has priced its initial public offering of 6 million units at $10 per unit valuing the IPO at $60 million. The units will trade on Nasdaq under the ticker PECEU starting May 22, 2026. The company is a blank check acquisition company aiming to target business combinations primarily in Asia, excluding Mainland China, Hong Kong, …
Pliant Therapeutics announced a poster presentation at the 2026 ASCO Annual Meeting highlighting their Phase 1b FORTIFY trial, which is evaluating PLN-101095, a dual integrin inhibitor, in combination with pembrolizumab for patients with immune checkpoint inhibitor refractory solid tumors. The trial is actively enrolling multiple patient cohorts an…
VCI Global Limited disclosed that NASDAQ notified the company of a delayed filing of its 2025 Form 20-F report. The company had previously filed a Form 12b-25 advising the SEC of the delay due to additional time needed for financial review. VCI Global is submitting a compliance plan to NASDAQ and may receive an extension of up to 180 days to regain…
Aktis Oncology announced first-in-human imaging and dosimetry results for AKY-2519, a novel miniprotein radioconjugate targeting B7-H3 expressing tumors, including metastatic castration-resistant prostate cancer and other solid tumors. Data presented at ASCO 2026 demonstrate robust tumor uptake and limited normal tissue exposure, indicating a favor…
Jupiter Neurosciences announced the closing of a $2 million registered direct offering, issuing over 7 million shares to strengthen its cash position. The capital raise extends the company's cash runway to fund its Phase 2a clinical trial for Parkinson’s disease and supports debt reduction efforts to improve shareholder equity. Additionally, funds …
Black Diamond Therapeutics announced positive Phase 2 clinical trial results of silevertinib, an oral brain-penetrant EGFR inhibitor, in treatment-naïve patients with non-small cell lung cancer (NSCLC) harboring non-classical EGFR mutations. The study demonstrated a median progression-free survival of 15.2 months, a 60% objective response rate, and…
Autolus Therapeutics announced publication and upcoming presentation of clinical data from the FELIX Phase Ib/II trial on their T cell therapy candidate obe-cel at the ASCO 2026 meeting. The data shows a 59% overall response rate and median duration of response of 42.6 months in adult patients with relapsed/refractory B-cell acute lymphoblastic leu…
